Disease Progression in Chronic Hepatitis B Patients under Long-Term Antiviral Therapy
BACKGROUND/AIMS: We investigated factors associated with the disease progression and development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients during long-term oral nucleos(t)ide analog (NA) therapy.
METHODS: This retrospective study included 524 naive CHB patients who received oral NA therapy for more than 48 weeks between January 2003 and December 2007. The primary outcome was 5-year cumulative probability of disease progression and HCC development. Disease progression was defined as cirrhosis development, cirrhotic complications, HCC or liver-related mortality.
RESULTS: For the 524 patients, the cumulative probabilities of disease progression and HCC development at 1, 2, 3, 4 and 5 years were 1.1%, 6.3%, 9.0%, 11.6%, and 16.2% and 0.2%, 1.8%, 3.6%, 5.8%, and 9.3%, respectively. In multivariate analysis, age >50 years (hazard ratio [HR], 1.05) and cirrhosis (HR, 2.95) were significant factors for disease progression. Similarly, age >50 years (HR, 1.05), family history of HCC (HR, 5.48), and cirrhosis (HR, 17.16) were significant factors for HCC development. Importantly, longer duration (>12 months) of maintained virological response (<20 IU/mL) reduced the risks of disease progression (HR, 0.19) and HCC development (HR, 0.09).
CONCLUSIONS: Longer duration of maintained virological response significantly reduces the risk of disease progression or HCC development in CHB patients undergoing long-term oral NA therapy.
| Errataetall: |
CommentIn: Gut Liver. 2015 May 23;9(3):265-6. - PMID 25918259 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Gut and liver - 9(2015), 3 vom: 23. Mai, Seite 395-404 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Moon, Jin Chang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 08.01.2016 Date Revised 13.11.2018 published: Print CommentIn: Gut Liver. 2015 May 23;9(3):265-6. - PMID 25918259 Citation Status MEDLINE |
|---|
| doi: |
10.5009/gnl14170 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM244264945 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM244264945 | ||
| 003 | DE-627 | ||
| 005 | 20231224134331.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5009/gnl14170 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0814.xml |
| 035 | |a (DE-627)NLM244264945 | ||
| 035 | |a (NLM)25473072 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Moon, Jin Chang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Disease Progression in Chronic Hepatitis B Patients under Long-Term Antiviral Therapy |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.01.2016 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Gut Liver. 2015 May 23;9(3):265-6. - PMID 25918259 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND/AIMS: We investigated factors associated with the disease progression and development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients during long-term oral nucleos(t)ide analog (NA) therapy | ||
| 520 | |a METHODS: This retrospective study included 524 naive CHB patients who received oral NA therapy for more than 48 weeks between January 2003 and December 2007. The primary outcome was 5-year cumulative probability of disease progression and HCC development. Disease progression was defined as cirrhosis development, cirrhotic complications, HCC or liver-related mortality | ||
| 520 | |a RESULTS: For the 524 patients, the cumulative probabilities of disease progression and HCC development at 1, 2, 3, 4 and 5 years were 1.1%, 6.3%, 9.0%, 11.6%, and 16.2% and 0.2%, 1.8%, 3.6%, 5.8%, and 9.3%, respectively. In multivariate analysis, age >50 years (hazard ratio [HR], 1.05) and cirrhosis (HR, 2.95) were significant factors for disease progression. Similarly, age >50 years (HR, 1.05), family history of HCC (HR, 5.48), and cirrhosis (HR, 17.16) were significant factors for HCC development. Importantly, longer duration (>12 months) of maintained virological response (<20 IU/mL) reduced the risks of disease progression (HR, 0.19) and HCC development (HR, 0.09) | ||
| 520 | |a CONCLUSIONS: Longer duration of maintained virological response significantly reduces the risk of disease progression or HCC development in CHB patients undergoing long-term oral NA therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Antiviral therapy | |
| 650 | 4 | |a Carcinoma, hepatocellular | |
| 650 | 4 | |a Disease progression | |
| 650 | 4 | |a Hepatitis B, chronic | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Kim, Seong Hun |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, In Hee |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Chang Hun |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Sang Wook |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Seung Ok |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Soo Teik |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Dae-Ghon |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gut and liver |d 2007 |g 9(2015), 3 vom: 23. Mai, Seite 395-404 |w (DE-627)NLM197725406 |x 2005-1212 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2015 |g number:3 |g day:23 |g month:05 |g pages:395-404 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5009/gnl14170 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2015 |e 3 |b 23 |c 05 |h 395-404 | ||